Medications to Manage Erythrocytosis / Elevated Hematocrit on Testosterone Cypionate: First-Line and Beyond

What the Depo-Testosterone label says

The Depo-Testosterone label for intramuscular testosterone cypionate lists polycythemia among hematologic adverse reactions, says hemoglobin and hematocrit should be checked periodically during long-term use, and reports venous thromboembolic events in people using testosterone products [2].

The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in men who already have an elevated hematocrit, and recommends monitoring hematocrit, serum testosterone and prostate cancer risk during the first year of treatment [7].

Dose and formulation: the changes with data behind them

Across 29 placebo-controlled randomized trials covering 3,393 men, every testosterone formulation raised mean hematocrit compared with placebo: intramuscular enanthate and cypionate by 4.0% (95% CI 2.9 to 5.1) and gel by 3.0% [5]. Intramuscular enanthate/cypionate rose significantly more than the patch; the other formulation comparisons were not significantly different [5].

A retrospective single-center review of 178 men followed for 3 years found erythrocytosis (hematocrit above 50%) in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets [8]. It was not randomized, and the injection group was younger (mean 42.5 years) with a higher starting hematocrit [8]. The 2025 systematic review likewise found intramuscular formulations, higher doses and older age associated with a higher risk of erythrocytosis [6].

An older meta-analysis of 19 randomized trials in men aged 45 and over (651 on testosterone, 433 on placebo) found testosterone-treated men nearly four times as likely to have a hematocrit above 50% (odds ratio 3.69, 95% CI 1.82 to 7.51), and called the hematocrit rise the most frequent adverse event of testosterone replacement [9].

A 2023 clinical consultation guide says providers should decrease or discontinue testosterone therapy when hematocrit exceeds 54%, until it normalizes [3]. Depo-Testosterone is labeled for 50 to 400 mg every 2 to 4 weeks [2].

Phlebotomy

A 2025 review says phlebotomy should be considered for symptom control in JAK2-unmutated erythrocytosis [1]. Another 2025 review says low-dose aspirin and/or phlebotomy might be considered on an individualized basis when there are hyperviscosity symptoms, cardiovascular comorbidities or a history of thrombosis, with phlebotomy frequency determined by symptom relief [4]. In polycythemia vera, phlebotomy remains the cornerstone of treatment [10].

Low-dose aspirin

Low-dose aspirin appears in the erythrocytosis reviews as part of cardiovascular risk optimization, alongside control of other cardiovascular risk factors [1][4]. In polycythemia vera, lower-dose aspirin has been shown to be safe and effective for microvascular symptoms such as erythromelalgia and headache, while excessive aspirin use is contraindicated [10].

Anticoagulants and the label

The label says androgens may increase sensitivity to oral anticoagulants, that the anticoagulant dose may require reduction, and that INR and prothrombin time should be monitored more often when testosterone is started or stopped [2]. Its adverse reaction list includes suppression of clotting factors II, V, VII and X and bleeding in patients on concomitant anticoagulant therapy [2].

When the hematocrit does not look like a drug effect

The most clinically relevant step in working up erythrocytosis is excluding polycythemia vera with JAK2 mutation screening, and relative polycythemia from volume contraction should also be considered [1]. There are no evidence-based treatment guidelines for JAK2 wild-type erythrocytosis [4]. The 2025 systematic review reported thromboembolic events in up to 2.7% of men on testosterone therapy [6].

What remains unsettled

A 2022 review describes the evidence that secondary erythrocytosis during testosterone therapy causes harm as scarce, and the hematocrit cutoffs in guidelines as appearing arbitrarily chosen [11]. Reviews of testosterone-induced erythrocytosis call the link to thromboembolic events unclear or inconclusive [12][13].